Regulus


UPDATE: Wedbush Raises Regulus Therapeutics Price Target Following Single Dose RG-101 Results

In a research report issued today, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Regulus Therapeutics (NASDAQ:RGLS) and raised the price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts